- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03123731
iSTEP - an mHealth Physical Activity and Diet Intervention for Persons With HIV
September 25, 2023 updated by: Brook Henry, University of California, San Diego
HIV is associated with a pattern of neurocognitive deficits, metabolic dysfunction, and an elevated risk for cardiovascular disease (CVD), phenomena that remain untreated despite the use of medications to control the disease.
This proposal will examine the effect of a personalized, automated, interactive mobile phone text message intervention (iSTEP) designed to increase moderate physical activity (PA), decrease sedentary behavior (SB), and promote a healthy Mediterranean-style diet (MedDiet) in persons living with HIV (PLWH).
The investigators propose that participants who receive the iSTEP intervention will increase the amount of physical activity, improve their diet, show a reduction in risk factors for CVD, and exhibit improved neurocognitive performance.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Recruitment Office
- Email: hnrprecruitment@ucsd.edu
Study Contact Backup
- Name: Brook L Henry, Ph.D.
- Phone Number: 619-543-4737
- Email: blhenry@ucsd.edu
Study Locations
-
-
California
-
San Diego, California, United States, 92103
- HIV Neurobehavioral Research Program
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- ability to provide informed consent
- HIV infection documented at the University of California, San Diego (UCSD) HIV Neurobehavioral Research Program (HNRP) or assessed by an HIV test at screening
- proficient in English
- physically capable of participating in moderate PA as screened by the Physical Activity Readiness Questionnaire
- consent from primary care physician to participate in the study
- able to consume walnuts - no nut allergies
Exclusion Criteria:
- any physical conditions that would prevent moderate physical activity or where moderate physical activity would represent a health risk for the individual, including a history of myocardial infarction or stroke
- unwillingness or inability to participate in daily text messaging
- tree nut allergy that would prevent walnut consumption or other food restrictions that would prevent participation in the Mediterranean-style diet intervention (e.g., unable to eat fish or use olive oil for cooking).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control Arm
Participants will wear a Fitbit but will not receive any additional elements of the iSTEP intervention.
|
Wearing Physical Activity Monitor
|
Experimental: iSTEP PA intervention
Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA) and reduce sedentary behavior, including setting weekly goals to increase average daily step counts.
|
Physical Activity Intervention
Physical Activity and Diet Intervention
|
Experimental: iSTEP PA and diet intervention
Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA), reduce sedentary behavior, and promote adherence to a Mediterranean-style diet.
Participants will also be administered diet counseling from a registered dietitian and receive weekly feedback on both physical activity and diet behaviors.
|
Physical Activity Intervention
Physical Activity and Diet Intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physical activity - steps per day
Time Frame: 6 months
|
Average number of daily steps recorded by the Fitbit
|
6 months
|
Diet History Questionnaire (DHQ)
Time Frame: Change from baseline to the 6-month visit after intervention
|
DHQ assessment of the percent of fat, carbohydrate, and protein intake in participant diet over the past month
|
Change from baseline to the 6-month visit after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sedentary behavior - minutes per day
Time Frame: Change from first week (Week 1) to last week (Week 24) of the intervention
|
Average daily minutes of sedentary behavior (counts < 100/minute) quantified by GT3X Actigraph
|
Change from first week (Week 1) to last week (Week 24) of the intervention
|
Fitness - 6-minute walk test (6MWT)
Time Frame: Change from baseline to the 6-month visit after intervention
|
Time to complete 6-minute walk test around a 30 yard course; the score is the total yard distance completed.
|
Change from baseline to the 6-month visit after intervention
|
Physical activity - moderate physical activity measured by actigraph
Time Frame: Change from first week (Week 1) to last week (Week 24) of the intervention
|
Average daily minutes of moderate physical activity quantified by GT3X Actigraph
|
Change from first week (Week 1) to last week (Week 24) of the intervention
|
Physical activity - daily energy expenditure
Time Frame: Change from first week (Week 1) to last week (Week 24) of the intervention
|
Seven-day Physical Activity Recall - kilocalories per day
|
Change from first week (Week 1) to last week (Week 24) of the intervention
|
Polyunsaturated fatty acids (PUFA) in plasma
Time Frame: Change from baseline to the 6-month visit after intervention
|
One reported value of the total PUFA amount, consisting of the sum of α-linoleic acid (ALA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA) levels in plasma.
|
Change from baseline to the 6-month visit after intervention
|
Carotenoids in plasma
Time Frame: Change from baseline to the 6-month visit after intervention
|
One reported value of the total carotenoid amount, consisting of the sum of alpha-carotene, beta-carotene, lutein, lycopene and betacryptoxanthin levels in plasma.
|
Change from baseline to the 6-month visit after intervention
|
Interleukin-6 (IL6)
Time Frame: Change from baseline to the 6-month visit after intervention
|
Levels of IL6 in plasma
|
Change from baseline to the 6-month visit after intervention
|
C-reactive protein (CRP)
Time Frame: Change from baseline to the 6-month visit after intervention
|
Levels of CRP in plasma
|
Change from baseline to the 6-month visit after intervention
|
D-dimer
Time Frame: Change from baseline to the 6-month visit after intervention
|
Levels of D-dimer in plasma
|
Change from baseline to the 6-month visit after intervention
|
Tumor necrosis factor alpha (TNFa)
Time Frame: Change from baseline to the 6-month visit after intervention
|
Levels of TNFa in plasma
|
Change from baseline to the 6-month visit after intervention
|
Total cholesterol (TC)
Time Frame: Change from baseline to the 6-month visit after intervention
|
Levels of TC in plasma
|
Change from baseline to the 6-month visit after intervention
|
Low density lipoprotein cholesterol (LDL-C)
Time Frame: Change from baseline to the 6-month visit after intervention
|
Levels of LDL-C in plasma
|
Change from baseline to the 6-month visit after intervention
|
High density lipoprotein cholesterol (HDL-C)
Time Frame: Change from baseline to the 6-month visit after intervention
|
Levels of HDL-C in plasma
|
Change from baseline to the 6-month visit after intervention
|
Triglycerides
Time Frame: Change from baseline to the 6-month visit after intervention
|
Levels of triglycerides in plasma
|
Change from baseline to the 6-month visit after intervention
|
Wechsler Adult Intelligence Scale (WAIS) Digit Symbol
Time Frame: Change from baseline to the 6-month visit after intervention
|
Neurocognitive assessment
|
Change from baseline to the 6-month visit after intervention
|
WAIS Symbol Search
Time Frame: Change from baseline to the 6-month visit after intervention
|
Neurocognitive assessment
|
Change from baseline to the 6-month visit after intervention
|
Trail Making Test Part A
Time Frame: Change from baseline to the 6-month visit after intervention
|
Neurocognitive assessment
|
Change from baseline to the 6-month visit after intervention
|
Trail Making Test Part B
Time Frame: Change from baseline to the 6-month visit after intervention
|
Neurocognitive assessment
|
Change from baseline to the 6-month visit after intervention
|
Hopkins Verbal Learning Test - Revised
Time Frame: Change from baseline to the 6-month visit after intervention
|
Neurocognitive assessment
|
Change from baseline to the 6-month visit after intervention
|
Brief Visuospatial Memory Test - Revised
Time Frame: Change from baseline to the 6-month visit after intervention
|
Neurocognitive assessment
|
Change from baseline to the 6-month visit after intervention
|
Wisconsin Card Sorting Test
Time Frame: Change from baseline to the 6-month visit after intervention
|
Neurocognitive assessment
|
Change from baseline to the 6-month visit after intervention
|
Controlled Oral Word Association Test
Time Frame: Change from baseline to the 6-month visit after intervention
|
Neurocognitive assessment
|
Change from baseline to the 6-month visit after intervention
|
Category Fluency
Time Frame: Change from baseline to the 6-month visit after intervention
|
Neurocognitive assessment
|
Change from baseline to the 6-month visit after intervention
|
WAIS Letter-Number Sequencing
Time Frame: Change from baseline to the 6-month visit after intervention
|
Neurocognitive assessment
|
Change from baseline to the 6-month visit after intervention
|
Paced Auditory Serial Addition Task
Time Frame: Change from baseline to the 6-month visit after intervention
|
Neurocognitive assessment
|
Change from baseline to the 6-month visit after intervention
|
Grooved Pegboard Test.
Time Frame: Change from baseline to the 6-month visit after intervention
|
Neurocognitive assessment
|
Change from baseline to the 6-month visit after intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Brook L Henry, Ph.D., University of California, San Diego
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2018
Primary Completion (Actual)
May 31, 2023
Study Completion (Actual)
May 31, 2023
Study Registration Dates
First Submitted
April 11, 2017
First Submitted That Met QC Criteria
April 18, 2017
First Posted (Actual)
April 21, 2017
Study Record Updates
Last Update Posted (Actual)
September 28, 2023
Last Update Submitted That Met QC Criteria
September 25, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- 161347
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV/AIDS
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of Massachusetts, BostonCompleted
-
Stanford UniversityJanssen Services, LLCCompleted
-
ViiV HealthcareJohns Hopkins University; Pfizer; Vanderbilt University; University of North Carolina...Completed
-
Medical College of WisconsinCompleted
-
Emory UniversityCompleted
-
Rhode Island HospitalUnknown
-
Tibotec Pharmaceuticals, IrelandCompleted
-
Lampiris, Harry W., M.D.AbbottUnknown
Clinical Trials on Control Arm
-
Centre Leon BerardNational Cancer Institute, France; Fondation de France; Cancéropôle Lyon Auvergne... and other collaboratorsCompletedImpact of Nutritional Intervention in Women With Breast Cancer Under Adjuvant Chemotherapy (PASAPAS)Breast Cancer | Adequate Physical ConditionFrance
-
Imperial College LondonKing Khalid UniversityRecruitingCardiovascular Diseases | Acute Coronary SyndromeUnited Kingdom
-
Kaiser PermanenteRecruitingAdolescent Behavior | Mental Health IssueUnited States
-
Heart of England NHS TrustAstraZenecaUnknown
-
McGill University Health Centre/Research Institute...Canadian Institutes of Health Research (CIHR); St. Justine's HospitalActive, not recruitingDiabetes Mellitus, Type 1 | Type1diabetes | Insulin Dependent DiabetesCanada
-
Lawson Health Research InstituteCompletedChronic Kidney DiseaseCanada
-
Herlev and Gentofte HospitalUniversity of Aarhus; Danish Cancer Society; The Novo Nordic Foundation; University...Recruiting
-
Kaiser Clinic and HospitalCompletedObesity | Weight GainBrazil
-
Duke UniversityTerumo BCTCompletedAllogenic Transfusion of Platelets During Cardiac SurgeryUnited States
-
Istituto Nazionale di Ricovero e Cura per AnzianiRecruitingStroke | Aging Problems | Innovative Rehabilitation Treatment Based on RoboticsItaly